Pharm Exec's 2015 Brand of the Year: Sovaldi and Harvoni for Hepatitis C

Pharm Exec's 2015 Brand of the Year: Sovaldi and Harvoni for Hepatitis C
Modern medicine is founded more on facts than faith. But for hepatitis C virus (HCV) patient Gavin West, the single pill drug Harvoni is not just a virus-wiping cure—it's a miracle. Ironically, it was April 3—Good Friday to millions of Christians …
Read more here.
New Hepatitis C Treatments Have High Cure Rates for African Americans
The epidemic of chronic hepatitis C virus (HCV) infection impacts over 3 million individuals in the United States, and over 50% of infected people are undiagnosed. In an effort to increase the number of people who are aware of their HCV infection and …
Read more here.

The Patient with Hepatitis C
Learning Objective: Upon successful completion of this educational activity, participants should be better able to evaluate treatment options for patients with hepatitis C virus (HCV) infection. Faculty: Ronald A. Codario, MD, FACP, FNLA, RPVI, CCMEP
Read more here.

Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks
A 6-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver cirrhosis, according to a …
Read more here.

Blue Cross Withholds Cure from Hepatitis C Patients, Lawsuit Claims
LOS ANGELES, May 15, 2015 /PRNewswire/ — Shernoff Bidart Echeverria Bentley LLP filed a lawsuit in Los Angeles Superior Court today accusing Blue Cross of withholding a cure for Hepatitis C based only upon profits, in violation of California law.
Read more here.

Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122
miR-122 is a liver-specific microRNA (miRNA) that binds to two sites (S1 and S2) on the 5′ untranslated region (UTR) of the hepatitis C virus (HCV) genome and promotes the viral life cycle. It positively affects viral RNA stability, translation, and …
Read more here.

PYPA alleged that the DRAP is deliberating delaying registration of a low
LAHORE: The Pakistan Young Pharmacists Association (PYPA) has alleged that the Drug Regulatory Authority Pakistan (DRAP) is deliberating delaying registration of a low-priced hepatitis C drug, ignoring the need of hundreds of millions of patients …
Read more here.

Achieving SVR can lessen economic impact of HCV, save billion
WASHINGTON — By treating hepatitis C virus with the latest medications and achieving sustained virologic response, physicians can predict a recoup of nearly $ 3 billion of the estimated $ 7 billion financial loss seen in the United States, according to …
Read more here.


Leave a Reply